News and Announcements
Treatment of the First Patient in XanADu Marks Landmark in Alzheimer’s Disease Trial
- Published May 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX: ACW) is delighted to announce the treatment of the first patient in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease. This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University in Scotland and Actinogen Medical in Australia, to develop Xanamem as a promising new treatment for Alzheimer’s disease.
KEY TAKEAWAYS:
- Actinogen Medical reaches a major milestone with the first patient enrolled into XanADu – its Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
- The first trial patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia.
- This marks a defining moment in the development of Xanamem following more than a decade of research.
- Xanamem blocks excess production of cortisol, the stress hormone, in the brain and represents a promising new approach to treat Alzheimer’s disease.
- XanADu will enrol 174 patients at 20 research sites in the USA, the UK and Australia with the final patientexpected in Q4 2018 and top-line results in Q1 2019.
Alzheimer’s expert Professor Colin Masters, AO, Laureate Professor at The University of Melbourne, one of the AIBL study’s key authors and a member of Actinogen’s Scientific Advisory Board, said Xanamem could provide the turning-point needed in finding a new effective treatment for Alzheimer’s disease.
“Earlier this year, the AIBL study, a 1100+ participant, 9-year study published data showing that raised cortisol is strongly associated with the development of Alzheimer’s disease. Xanamem, through its inhibition of cortisol in the brain, could represent a major advance in the treatment of Alzheimer’s,” he said.
“I am delighted that Australia is at the forefront of global Alzheimer’s research in initiating the XanADu trial, evaluating Xanamem as a treatment for this devastating disease.”
Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
